跳至主要內容

新聞與行事曆

新聞: 截至 2026-10-11
這些標記是什麼意思

重要性是模型對已發布報導給出的 1–5 分,不是對市場的預測。

已排定事件列上的影響是公司顯著度層級(高/中由圖譜中心度與規模判定;低僅用於人工整理的次要事件),不是對波動幅度的預測。

標記為已確認的財報日期,是 Yahoo Finance 認定由公司確認的;預估表示尚未公布。未加標記的列沒有可查的出處記錄。

經濟數據發布屬於總體經濟、不歸屬任何產業,因此在任何檢視下都會保留。沒有數值的發布表示尚未公布,頁面會直說,而不是顯示為零。

涵蓋被追蹤公司的即將到來的事件;已過去的事件會歸檔,並在可得時補上結果——這些結果都經人工整理並附引用,絕不杜撰。沒有結果的歷史列會顯示「結果待定」。

閉鎖期屆滿或指數調整的列會多出一行算術——將變得可賣出的股數,或指數基金必須買進的股數,以佔流通股的比例表示——依招股說明書或指數編製方法讀出,兩個數字都在該列註明出處。它陳述的是機制,不是價格走勢。由 IPO + 180 天推算出的閉鎖期日期會一直標為預估,直到公司自己說明為止。

未來

已排定 · 今天與明天 · 行事曆更新於 2026-10-12

10月12日週一 · 今天

10月13日週二

過往

已發布 · 最新在前

8月3日週一

合作

11:01
GlobeNewswire

X-energy, SGL Carbon Announce Capacity Expansion for Nuclear-Grade Graphite

X-energy and SGL Carbon announced an agreement that would expand the supply chain for a critical long-lead material, supporting execution of X-energy's 11+ GW commercial pipeline. The release describes facility upgrades at SGL's Chedde, France site and expanded U.S. machining capacity.

大盤 開啟原文 ↗

7月31日週五

產品

18:24
Yahoo Finance

Novo Nordisk Shares Sink After Heart Disease Drug Candidate Fails Late-Stage Trial

Novo Nordisk shares fell after a late-stage trial of ziltivekimab was unable to reduce major adverse cardiovascular events compared with a placebo, a setback for the company's cardiovascular pipeline.

大盤 開啟原文 ↗

7月30日週四

財報

20:15
GlobeNewswire

Eversource Energy Reports Second Quarter 2026 Results

Eversource Energy reported second-quarter 2026 "GAAP earnings of $53.7 million, or $0.14 per share," and "Non-GAAP recurring earnings totaled $329.1 million, or $0.87 per share." The company reaffirmed "2026 non-GAAP recurring earnings of between $4.57 per share and $4.72 per share" and a "cumulative long-term earnings per share growth rate within the range of 5 to 7 percent through 2030."

大盤 開啟原文 ↗

財報

20:04
SEC EDGAR

First Solar, Inc. Announces Second Quarter 2026 Financial Results and Reaffirms Guidance

First Solar reported Q2 2026 net sales of $1.06 billion, "a decrease of 4% year-over-year," and net income of $423 million, or $3.92 per diluted share, versus $342 million or $3.18 per diluted share a year earlier. Adjusted EBITDA was $644 million. The company reaffirmed its 2026 guidance and reported a "Contracted sales backlog of 45.1 GW as of June 30, 2026," noting it "surpassed 100 GW of cumulative module sales globally."

大盤 開啟原文 ↗

財報

13:38
GlobeNewswire

Sanofi's half-year financial report for 2026

Sanofi announced the availability of its half-year financial report for the period ended June 30, 2026, filed with French and US regulators. The release points to Q2 results reporting "Q2 sales growth of 17.8% at CER" and "business earnings per share (EPS) of EUR 2.09," with "2026 guidance upgraded."

大盤 開啟原文 ↗

原始消息流

所有到達的消息 · 7 天